博迅生物
(836504)
| 流通市值：4.62亿 | | | 总市值：11.72亿 |
| 流通股本：1709.77万 | | | 总股本：4333.31万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 23,152,939.5 | 122,161,362.98 | 84,213,151.32 | 55,794,252.8 |
| 营业收入 | 23,152,939.5 | 122,161,362.98 | 84,213,151.32 | 55,794,252.8 |
| 二、营业总成本 | 20,703,452.66 | 109,497,810.76 | 77,306,703.9 | 52,010,999.53 |
| 营业成本 | 12,642,845.9 | 72,996,889.39 | 50,665,299.57 | 33,940,655.32 |
| 税金及附加 | 135,292.92 | 1,038,254.36 | 679,449.6 | 461,371.48 |
| 销售费用 | 2,126,718.39 | 11,620,319.46 | 8,962,364.72 | 6,540,675.71 |
| 管理费用 | 4,443,799.22 | 17,054,353.65 | 12,329,994.04 | 8,120,904.62 |
| 研发费用 | 1,332,779.7 | 6,781,632.54 | 4,685,125.05 | 3,018,588.68 |
| 财务费用 | 22,016.53 | 6,361.36 | -15,529.08 | -71,196.28 |
| 其中:利息费用 | 184,601.74 | 1,238,220.66 | 334,471.08 | 235,133.7 |
| 其中:利息收入 | 180,255.94 | 1,303,756.81 | 419,121.55 | 353,574.99 |
| 加:公允价值变动收益 | 100,313.25 | 122,431.53 | 94,605.95 | 103,879.72 |
| 加:投资收益 | 217,166.56 | 1,948,153.09 | 1,142,545.97 | 884,365.5 |
| 资产减值损失(新) | -923,935.07 | -835,520.27 | -634,223.12 | -279,498.71 |
| 信用减值损失(新) | -797,331.87 | 47,021.77 | -1,000,828.26 | -1,253,736.39 |
| 其他收益 | 400,430.31 | 4,424,507.93 | 3,048,693.74 | 1,412,028.58 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,446,130.02 | 18,370,146.27 | 9,557,241.7 | 4,650,291.97 |
| 加:营业外收入 | 17,539.56 | 224,344.76 | 33,194.32 | - |
| 减:营业外支出 | 2,739.79 | 482,498.92 | 425,607.82 | 265,557.05 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,460,929.79 | 18,111,992.11 | 9,164,828.2 | 4,384,734.92 |
| 减:所得税费用 | 221,281.46 | 2,301,550.69 | 988,934.75 | 499,042.1 |
| 六、净利润 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 | 3,885,692.82 |
| 持续经营净利润 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 | 3,885,692.82 |
| 归属于母公司股东的净利润 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 | 3,885,692.82 |
| (一)基本每股收益 | 0.03 | 0.36 | 0.19 | 0.09 |
| (二)稀释每股收益 | 0.03 | 0.36 | 0.19 | 0.09 |
| 九、综合收益总额 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 | 3,885,692.82 |
| 归属于母公司股东的综合收益总额 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 | 3,885,692.82 |
| 公告日期 | 2025-04-28 | 2025-04-07 | 2024-10-30 | 2024-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |